Articles tagged "Non-invasive diagnosis"

2018 American Transplant Congress
Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection
J. Assaker,¹ A. Srivastava,¹ J. Hurley,² B. Al Doujailan,¹ S. Eskandari,¹ C. Coticchia,² M. Mohamed,¹ S. Bentink,² V. Tadigotla,² L. Riella,¹ A. Chandraker,¹ J. Skog,² J. Azzi.¹
¹Transplantation Renal Center, BWH and BCH, Boston; ²Exosome Diagnostic Inc., Cambridge.
Kidney transplant rejection leads to short and long-term adverse clinical outcomes. Serum creatinine is a suboptimal late biomarker for rejection. Exosomes are nanometer-sized vesicles released…
2018 American Transplant Congress
Acute Tubular and Glomerular Kidney Injury Markers Reflect Ischemia-Reperfusion and Rejection
Y. Shim, R. Fan, N. Dvorina, W. Baldwin.
Immunology, Cleveland Clinic, Cleveland, OH.
Reliable markers of early acute injury following renal transplantation would enable timely therapeutic interventions. Standard serum creatinine and blood urea nitrogen measurements increase only after…
2018 American Transplant Congress
Non-Invasive Imaging Modalities for Immune Monitoring of Vascularized Composite Allografts Using a Translational Large Animal Model
J. Etra,¹ K. Cilwa,² G. Furtmueller,¹ A. Leto Barone,¹ K. Kolegraff,¹ E. Elster,¹ W. Lee,¹ G. Brandacher.¹
¹Department of Plastic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Naval Medical Research Center, Silver Springs, MD; ³Department of Surgery, Uniformed Services, University of Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD.
PurposeImmunological complications and skin rejection remains an obstacle in broadening the applicability of vascularized composite allotransplantation (VCA). Currently, diagnosis of rejection relies on skin biopsies…
2017 American Transplant Congress
Non-Invasive Detection of Rejection with ImmunoPET Imaging.
D. Mathews,¹ K. Lindsay,² P. Santangelo,² Y. Dong,¹ J. Tso,³ A. Adams.¹
¹Department of Surgery, Emory University, Atlanta, GA; ²Department of Biomedical Engineering, Georgia Tech, Atlanta, GA; ³JN Biosciences LLC, Mountain View, CA
Current approaches to detect and diagnose rejection are retrospective and/or invasive. These methods assess the extent of end organ damage by insensitive and non-specific measures…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Correlates with Antibody-Mediated Rejection in Kidney Allografts.
R. Bloom,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Sninsky,⁴ J. Yee,⁴ D. Brennan.⁵
¹University of Pennsylvania, Philadelphia, PA; ²University of Maryland, Baltimore, MD; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵Washington University, St. Louis, MO
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may enable more frequent, quantitative, and safer assessment of allograft rejection and…
2017 American Transplant Congress
The Role of Urinary Chemokines in Distinguishing Causes of Renal Allograft Dysfunction.
S. Chong,¹ R. Fernando,² M. Harber,¹ C. Magee.¹
¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom; ²Anthony Nolan Laboratories, Royal Free Hospital, London, United Kingdom
The aetiology of renal transplant dysfunction is varied, and diagnosis often relies upon transplant biopsy, an invasive procedure that carries significant risk. Availability of a…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.
D. Brennan,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ J. Sninsky,⁴ R. Woodward,⁴ J. Yee,⁴ R. Bloom.⁵
¹Washington University, St. Louis, MO; ²University of Maryland, Baltimore, MD; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) has shown promise as a biomarker in identification of allograft rejection. Here we report on the changes in dd-cfDNA prior…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.
J. Bromberg,¹ D. Brennan,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Yee,⁴ J. Sninsky,⁴ R. Bloom.⁵
¹University of Maryland, Baltimiore, MD; ²Washington University, St. Louis, MO; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the circulating blood of transplant recipients has shown promise as a non-invasive biomarker of acute rejection. This analysis was…
2017 American Transplant Congress
Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts.
K. Keslar,¹ A. Zmijewska,² J. Chen,² K. Newell,³ P. Heeger,⁴ R. Mannon,² R. Fairchild.¹
¹Department of Immunology, Cleveland Clinic, Cleveland, OH; ²Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL; ³Department of Surgery, Emory University, Atlanta, GA; ⁴Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY
A major goal of the Clinical Trials in Organ Transplantation (CTOT) studies is the identification of biomarkers that predict or diagnose acute graft rejection in…
2016 American Transplant Congress
NanoString Detection of Gene Signatures in Urine During Acute Cellular Rejection of Kidney Grafts.
K. Keslar,¹ A. Zmijewska,² J. Andriga,² K. Newell,³ R. Mannon,² P. Heeger,⁴ R. Fairchild.¹
¹Cleveland Clinic, Cleveland; ²UAB, Birmingham; ³Emory, Atlanta; ⁴MSSM, New York.
Considerable effort has focused on identification of gene expression patterns that may assist in diagnosis of acute cellular rejection. The NanoString platform offers a novel…